

Chemicals/Finland, September 17, 2021 Company update

## Temporary profitability challenges

Exel's margins take a hit this year, but we see Exel's favorable positioning will remain intact and next year's results should more than make up for the interim dip.

#### The negative factors have been discussed earlier

Exel issued a negative profit warning yesterday. The company's earlier outlook guided revenue as well as adj. EBIT to increase, whereas the updated guidance says revenue is to increase significantly while adj. EBIT is to decrease. We don't view the revenue update a major surprise but the FY '21 profitability downgrade is negative news. According to Exel raw material availability has weakened, and both material as well as logistics costs have increased. Exel also says certain high volume carbon fiber Wind power customer applications have generated low margins during their ramp-up phase. These negative factors were discussed already over the spring and summer, but we expected margin improvement in H2 after some softness seen in Q2.

#### We expect profitability back to high levels in FY '22

We already expected strong top line growth for this year and thus we revise our estimate only a bit, from EUR 124.9m to EUR 125.8m. Our previous adj. EBIT estimate for FY '21 was EUR 10.8m, which we now revise down to EUR 8.9m. We estimate 17% y/y revenue growth for Q3 (Exel grew 23% y/y in Q2). We now expect EUR 1.9m in Q3 adj. EBIT (prev. EUR 2.7m), a bit below the EUR 2.0m comparison figure. We therefore estimate Q3 EBIT margin to have softened to 6.3%. We now expect 6.8% margin for Q4, in other words EUR 2.1m EBIT (prev. EUR 3.2m). In our view Exel's composites pricing will adjust to higher raw materials prices going forward and hence the company should be able to make up for the interim profitability drop next year when the raw materials and logistics markets have normalized.

#### We still consider valuation not very demanding

Our FY '22 revenue estimate is EUR 139.0m (prev. EUR 137.4m), while we revise our EBIT estimate down to EUR 12.4m (prev. EUR 13.5m). The 8.9% EBIT margin estimate is in line with the figure seen last year while our corresponding top line estimate is 28% above the EUR 108.6m in FY '20 revenue. Exel is valued 9x EV/EBITDA and 15x EV/EBIT on our FY '21 estimates. These levels are not that low but turn attractive at ca. 7x and 10x on our FY '22 estimates. Our new TP is EUR 10.0 (11.5); retain BUY rating.



■ BUY □ HOLD ■ SELL

www.exelcomposites.com

joonas.ilvonen@evli.com

Joonas Ilvonen

+358 44 430 9071

| KEY FIGU    | RES           |              |           |                 |            |            |                    |                |                |            |  |
|-------------|---------------|--------------|-----------|-----------------|------------|------------|--------------------|----------------|----------------|------------|--|
|             | Sales<br>EURm | EBIT<br>EURm | EBIT<br>% | FCF<br>EURm     | EPS<br>EUR | P/E<br>(x) | EV/Sales<br>(x)    | EV/EBIT<br>(x) | FCF yield<br>% | DPS<br>EUR |  |
| 2019        | 103.8         | 5.1          | 4.9%      | 0.7             | 0.20       | 32.5       | 1.0                | 21.0           | 0.9            | 0.18       |  |
| 2020        | 108.6         | 9.4          | 8.7%      | 0.5             | 0.45       | 16.4       | 1.1                | 12.5           | 0.6            | 0.20       |  |
| 2021E       | 125.8         | 8.8          | 7.0%      | 3.2             | 0.50       | 17.1       | 1.0                | 15.0           | 3.2            | 0.25       |  |
| 2022E       | 139.0         | 12.4         | 8.9%      | 6.5             | 0.73       | 11.8       | 0.9                | 10.3           | 6.4            | 0.30       |  |
| 2023E       | 149.5         | 14.6         | 9.8%      | 8.6             | 0.88       | 9.8        | 0.8                | 8.4            | 8.4            | 0.32       |  |
| Market cap  | o, EURm       |              | 102 G     | earing 2021E,   | 0/0        |            | 90.5 CAGR          | EPS 2020-2     | 3, %           | 24.7       |  |
| Net debt 2  | 021E, EURm    |              | 29 P      | rice/book 2021  | 1 E        |            | 3.2 CAGR           | sales 2020-    | 23, %          | 11.2       |  |
| Enterprise  | value, EURm   |              | 131 D     | ividend yield 2 | 2021E, %   |            | 2.9 ROE 2          | 021E, %        |                | 19.6       |  |
| Total asset | s 2021E, EURn | n            | 105 Ta    | ax rate 2021E,  | %          |            | 25.6 ROCE 2021E, % |                |                |            |  |
| Goodwill 2  | 021E, EURm    |              | 13 E      | quity ratio 202 | 21E, %     |            | 30.7 PEG, F        | P/E 21/CAGR    |                | 0.7        |  |

Web site

Analyst

E-mail

Telephone



Chemicals/Finland, September 17, 2021 Company update

## Estimates and peer group multiples

| Exel Composites                | 2019  | Q1'20 | Q2'20  | Q3'20 | Q4'20 | 2020  | Q1'21 | Q2'21 | Q3'21e | Q4'21e | 2021e |
|--------------------------------|-------|-------|--------|-------|-------|-------|-------|-------|--------|--------|-------|
| Buildings and infrastructure   | 23.5  | 6.2   | 5.3    | 4.9   | 7.0   | 23.5  | 7.0   | 8.7   | 6.8    | 7.9    | 30.4  |
| Equipment and other industries | 18.6  | 6.1   | 4.0    | 4.3   | 5.1   | 19.5  | 5.6   | 5.2   | 4.7    | 5.4    | 20.9  |
| Wind power                     | 23.6  | 5.8   | 7.9    | 7.8   | 6.6   | 28.1  | 7.4   | 7.8   | 9.0    | 7.6    | 31.7  |
| Machinery and electrical       | 14.4  | 3.8   | 4.8    | 3.3   | 3.7   | 15.5  | 3.7   | 5.1   | 3.5    | 4.0    | 16.2  |
| Transportation                 | 13.1  | 3.4   | 2.8    | 2.2   | 1.9   | 10.2  | 2.5   | 2.7   | 2.3    | 2.0    | 9.5   |
| Defense                        | 2.3   | 1.3   | 8.0    | 1.9   | 1.4   | 5.3   | 2.2   | 1.8   | 2.2    | 2.0    | 8.2   |
| Telecommunications             | 8.2   | 1.2   | 1.7    | 1.7   | 1.8   | 6.5   | 2.5   | 2.3   | 1.9    | 2.1    | 8.8   |
| Revenue                        | 103.8 | 27.8  | 27.2   | 26.0  | 27.5  | 108.6 | 31.0  | 33.5  | 30.4   | 31.0   | 125.8 |
| y/y change, %                  | 7 %   | 3 %   | 3 %    | 10 %  | 3 %   | 5 %   | 11 %  | 23 %  | 17 %   | 13 %   | 16 %  |
| Adjusted EBIT                  | 7.2   | 2.1   | 2.9    | 2.0   | 2.7   | 9.7   | 2.5   | 2.5   | 1.9    | 2.1    | 8.9   |
| EBIT                           | 5.1   | 1.9   | 2.8    | 2.0   | 2.7   | 9.4   | 2.4   | 2.4   |        |        | 8.8   |
| -margin, %                     | 6.9 % | 7.5 % | 10.6 % | 7.8 % | 9.9 % | 8.9 % | 7.9 % | 7.3 % | 6.3 %  | 6.8 %  | 7.1 % |
| -margin (reported), %          | 4.9 % | 6.7 % | 10.2 % | 7.8 % | 9.9 % | 8.7 % | 7.8 % | 7.0 % |        |        | 7.0 % |

Source: Evli Research

|                             | MCAP |       | EV/EBITDA |       |        | EV/EBIT |       |         | EBIT-% |        |
|-----------------------------|------|-------|-----------|-------|--------|---------|-------|---------|--------|--------|
| EXEL COMPOSITES PEER GROUP  | MEUR | 20    | 21        | 22    | 20     | 21      | 22    | 20      | 21     | 22     |
| Gurit Holding               | 768  |       | 14.8x     | 12.7x |        | 20.0x   | 16.1x | 11.1 %  | 8.5 %  | 10.0 % |
| Hexagon Composites          | 623  | 58.0x | 79.4x     | 42.8x |        |         |       | -1.9 %  | -5.0 % | -3.0 % |
| Hexcel                      | 4162 | 26.6x | 29.3x     | 18.3x | 351.9x | 110.6x  | 32.2x | 0.9 %   | 3.8 %  | 11.0 % |
| Avient                      | 3645 | 13.0x | 9.8x      | 9.0x  | 18.9x  | 13.4x   | 12.0x | 8.1 %   | 9.3 %  | 9.8 %  |
| SGL Carbon                  | 1264 | 7.2x  | 12.1x     | 10.0x |        | 26.8x   | 18.3x | -10.9 % | 5.7 %  | 7.9 %  |
| TPI Composites              | 1111 | 22.7x | 20.7x     | 12.3x | 85.8x  |         | 26.2x | 1.5 %   | 0.0 %  | 3.3 %  |
| Peer Group Average          | 1929 | 25.5x | 27.7x     | 17.5x | 152.2x | 42.7x   | 20.9x | 1.5 %   | 3.7 %  | 6.5 %  |
| Peer Group Median           | 1188 | 22.7x | 17.8x     | 12.5x | 85.8x  | 23.4x   | 18.3x | 1.2 %   | 4.8 %  | 8.9 %  |
| Exel Composites (Evli est.) | 102  | 7.7x  | 8.8x      | 7.0x  | 12.5x  | 15.0x   | 10.3x | 8.7 %   | 7.0 %  | 8.9 %  |

-44 %

-85 %

-36 %

-66 %

-51 %

-43 %

613 %

47 %

0%

Exel Composites prem./disc. to peer median

Source FactSet, Evli Research

Chemicals/Finland, September 17, 2021 Company update

| VALUATION RESULTS        | BASE CASE DETAILS          | VALUATION ASSUMPTIONS  | ASSUMPTIONS FOR WACC           |      |
|--------------------------|----------------------------|------------------------|--------------------------------|------|
| Current share price      | 8.59 PV of Free Cash Flow  | 78 Long-term growth, % | 1.5 Risk-free interest rate, % | 2.25 |
| DCF share value          | 12.41 PV of Horizon value  | 102 WACC, %            | 8.5 Market risk premium, %     | 5.8  |
| Share price potential, % | 44.5 Unconsolidated equity | O Spread, %            | 0.5 Debt risk premium, %       | 3.3  |
| Maximum value            | 13.6 Marketable securities | 12 Minimum WACC, %     | 8.0 Equity beta coefficient    | 1.00 |
| Minimum value            | 11.4 Debt - dividend       | -44 Maximum WACC, %    | 9.0 Target debt ratio, %       | 10   |
| Horizon value, %         | 56.6 Value of stock        | 148 Nr of shares, Mn   | 11.9 Effective tax rate, %     | 21   |

| DCF valuation, EURm        | 2020 | 2021E | 2022E | 2023E | 2024E      | 2025E      | 2026E | 2027E      | 2028E | 2029E      | 2030E | Horizon |
|----------------------------|------|-------|-------|-------|------------|------------|-------|------------|-------|------------|-------|---------|
| Net sales                  | 109  | 126   | 139   | 149   | 157        | 162        | 166   | 169        | 172   | 176        | 178   | 181     |
| Sales growth, %            | 4.6  | 15.9  | 10.5  | 7.5   | 5.0        | 3.0        | 2.5   | 2.0        | 2.0   | 2.0        | 1.5   | 1.5     |
| Operating income (EBIT)    | 9    | 9     | 12    | 15    | 16         | 17         | 17    | 18         | 19    | 20         | 21    | 21      |
| Operating income margin, % | 8.7  | 7.0   | 8.9   | 9.8   | 10.2       | 10.5       | 10.5  | 10.5       | 11.0  | 11.5       | 11.5  | 11.5    |
| + Depreciation+amort.      | 6    | 6     | 6     | 6     | 6          | 6          | 6     | 5          | 5     | 5          | 6     |         |
| EBITDA                     | 15   | 15    | 18    | 21    | 22         | 23         | 23    | 23         | 24    | 26         | 26    |         |
| - Paid taxes               | -3   | -2    | -3    | -4    | -4         | -4         | -4    | <b>-</b> 5 | -5    | -5         | -5    |         |
| - Change in NWC            | 3    | -2    | -2    | -1    | -1         | -1         | 0     | 0          | 0     | 0          | 0     |         |
| NWC / Sales, %             | 11.2 | 11.3  | 11.4  | 11.4  | 11.5       | 11.5       | 11.5  | 11.5       | 11.5  | 11.6       | 11.6  |         |
| + Change in other liabs    | 0    | 0     | 0     | 0     | 0          | 0          | 0     | 0          | 0     | 0          | 0     |         |
| - Operative CAPEX          | -13  | -5    | -5    | -5    | <b>-</b> 5 | <b>-</b> 5 | -5    | <b>-</b> 5 | -5    | <b>-</b> 5 | -5    |         |
| opCAPEX / Sales, %         | 11.9 | 5.4   | 4.6   | 4.3   | 4.1        | 3.9        | 3.9   | 3.4        | 3.4   | 3.4        | 3.3   |         |
| - Acquisitions             | 0    | 0     | 0     | 0     | 0          | 0          | 0     | 0          | 0     | 0          | 0     |         |
| + Divestments              | 0    | 0     | 0     | 0     | 0          | 0          | 0     | 0          | 0     | 0          | 0     |         |
| - Other items              | 0    | 0     | 0     | 0     | 0          | 0          | 0     | 0          | 0     | 0          | 0     |         |
| = FCFF                     | 2    | 5     | 8     | 10    | 12         | 13         | 13    | 13         | 14    | 15         | 15    | 218     |
| = Discounted FCFF          |      | 5     | 8     | 9     | 9          | 9          | 9     | 8          | 8     | 7          | 7     | 102     |
|                            |      |       |       |       |            |            |       |            |       |            |       |         |
| = DFCF min WACC            |      | 5     | 8     | 9     | 9          | 9          | 9     | 8          | 8     | 8          | 7     | 114     |
| = DFCF max WACC            |      | 5     | 7     | 9     | 9          | 9          | 8     | 8          | 7     | 7          | 7     | 91      |

Chemicals/Finland, September 17, 2021 Company update

#### INTERIM FIGURES

| EVLI ESTIMATES, EURm                 | 2020Q1 | 2020Q2 | 2020Q3 | 2020Q4 | 2020  | 2021Q1 | 2021Q2 | 2021Q3E | 2021Q4E | 2021E | 2022E | 2023E |
|--------------------------------------|--------|--------|--------|--------|-------|--------|--------|---------|---------|-------|-------|-------|
| Net sales                            | 27.8   | 27.2   | 26.1   | 27.5   | 108.6 | 31.0   | 33.5   | 30.4    | 31.0    | 125.8 | 139.0 | 149.5 |
| EBITDA                               | 3.4    | 4.3    | 3.5    | 4.1    | 15.3  | 4.0    | 3.9    | 3.4     | 3.6     | 14.9  | 18.2  | 20.5  |
| EBITDA margin (%)                    | 12.1   | 15.8   | 13.5   | 14.8   | 14.1  | 13.0   | 11.7   | 11.2    | 11.6    | 11.9  | 13.1  | 13.7  |
| EBIT                                 | 1.9    | 2.8    | 2.0    | 2.7    | 9.4   | 2.4    | 2.4    | 1.9     | 2.1     | 8.8   | 12.4  | 14.6  |
| EBIT margin (%)                      | 6.7    | 10.3   | 7.8    | 9.9    | 8.7   | 7.8    | 7.0    | 6.3     | 6.8     | 7.0   | 8.9   | 9.8   |
| Net financial items                  | -0.6   | 0.2    | -0.7   | -1.2   | -2.3  | 0.5    | -0.5   | -0.4    | -0.4    | -0.8  | -0.7  | -0.6  |
| Pre-tax profit                       | 1.3    | 2.9    | 1.3    | 1.5    | 7.1   | 2.9    | 1.9    | 1.5     | 1.7     | 8.0   | 11.6  | 14.0  |
| Tax                                  | -0.6   | -0.4   | -0.2   | -0.4   | -1.7  | -0.9   | -0.5   | -0.3    | -0.4    | -2.1  | -3.0  | -3.6  |
| Tax rate (%)                         | 49.4   | 15.3   | 15.1   | 29.4   | 24.6  | 30.8   | 25.4   | 21.0    | 21.0    | 25.6  | 25.6  | 25.6  |
| Net profit                           | 0.7    | 2.5    | 1.1    | 1.1    | 5.4   | 2.0    | 1.4    | 1.2     | 1.3     | 6.0   | 8.7   | 10.4  |
| EPS                                  | 0.06   | 0.21   | 0.09   | 0.09   | 0.45  | 0.17   | 0.12   | 0.10    | 0.11    | 0.50  | 0.73  | 0.88  |
| EPS adjusted (diluted no. of shares) | 0.06   | 0.21   | 0.09   | 0.09   | 0.45  | 0.17   | 0.12   | 0.10    | 0.11    | 0.50  | 0.73  | 0.88  |
| Dividend per share                   | 0.00   | 0.00   | 0.00   | 0.00   | 0.20  | 0.00   | 0.00   | 0.00    | 0.00    | 0.25  | 0.30  | 0.32  |
| SALES, EURm                          |        |        |        |        |       |        |        |         |         |       |       |       |
| Exel Composites                      | 27.8   | 27.2   | 26.1   | 27.5   | 108.6 | 31.0   | 33.5   | 30.4    | 31.0    | 125.8 | 139.0 | 149.5 |
| Total                                | 27.8   | 27.2   | 26.1   | 27.5   | 108.6 | 31.0   | 33.5   | 30.4    | 31.0    | 125.8 | 139.0 | 149.5 |
| SALES GROWTH, Y/Y %                  |        |        |        |        |       |        |        |         |         |       |       |       |
| Exel Composites                      | 2.6    | 2.6    | 10.5   | 3.4    | 4.6   | 11.3   | 23.3   | 16.3    | 12.7    | 15.9  | 10.5  | 7.5   |
| Total                                | 2.6    | 2.6    | 10.5   | 3.4    | 4.6   | 11.3   | 23.3   | 16.3    | 12.7    | 15.9  | 10.5  | 7.5   |
| EBIT, EURm                           |        |        |        |        |       |        |        |         |         |       |       |       |
| Exel Composites                      | 1.9    | 2.8    | 2.0    | 2.7    | 9.4   | 2.4    | 2.4    | 1.9     | 2.1     | 8.8   | 12.4  | 14.6  |
| Total                                | 1.9    | 2.8    | 2.0    | 2.7    | 9.4   | 2.4    | 2.4    | 1.9     | 2.1     | 8.8   | 12.4  | 14.6  |
| EBIT margin, %                       |        |        |        |        |       |        |        |         |         |       | ·     |       |
| Exel Composites                      | 6.7    | 10.3   | 7.8    | 9.9    | 8.7   | 7.8    | 7.0    | 6.3     | 6.8     | 7.0   | 8.9   | 9.8   |
| Total                                | 6.7    | 10.3   | 7.8    | 9.9    | 8.7   | 7.8    | 7.0    | 6.3     | 6.8     | 7.0   | 8.9   | 9.8   |

Chemicals/Finland, September 17, 2021 Company update

| INCOME STATEMENT, EURm                   | 2016 | 2017   | 2018 | 2019   | 2020   | 2021E  | 2022E           | 2023E |
|--|------|--------|------|--------|--------|--------|-----------------|-------|
| Sales                                    | 73.1 | 86.3   | 96.6 | 103.8  | 108.6  | 125.8  | 139.0           | 149.5 |
| Sales growth (%)                         | -8.9 | 18.1   | 11.9 | 7.5    | 4.6    | 15.9   | 10.5            | 7.5   |
| EBITDA                                   | 3.8  | 9.3    | 7.7  | 10.7   | 15.3   | 14.9   | 18.2            | 20.5  |
| EBITDA margin (%)                        | 5.2  | 10.8   | 8.0  | 10.3   | 14.1   | 11.9   | 13.1            | 13.7  |
| Depreciation                             | -3.2 | -3.2   | -5.5 | -5.6   | -5.8   | -6.2   | -5.8            | -5.9  |
| EBITA                                    | 0.6  | 6.1    | 2.2  | 5.1    | 9.4    | 8.8    | 12.4            | 14.6  |
| Goodwill amortization / writedown        | 0.0  | 0.0    | 0.0  | 0.0    | 0.0    | 0.0    | 0.0             | 0.0   |
| EBIT                                     | 0.6  | 6.1    | 2.2  | 5.1    | 9.4    | 8.8    | 12.4            | 14.6  |
| EBIT margin (%)                          | 0.8  | 7.1    | 2.3  | 4.9    | 8.7    | 7.0    | 8.9             | 9.8   |
| Reported EBIT                            | -1.2 | 6.1    | 2.2  | 5.1    | 9.4    | 8.8    | 12.4            | 14.6  |
| EBIT margin (reported) (%)               | -1.6 | 7.1    | 2.3  | 4.9    | 8.7    | 7.0    | 8.9             | 9.8   |
| Net financials                           | -0.1 | -0.7   | -0.5 | -1.2   | -2.3   | -0.8   | -0.7            | -0.6  |
| Pre-tax profit                           | 0.5  | 5.4    | 1.7  | 3.9    | 7.1    | 8.0    | 11.6            | 14.0  |
| Taxes                                    | -0.2 | -1.2   | -1.3 | -1.5   | -1.7   | -2.1   | -3.0            | -3.6  |
| Minority shares                          | 0.0  | 0.0    | 0.0  | 0.0    | 0.0    | 0.0    | 0.0             | 0.0   |
| Net profit                               | -1.4 | 4.2    | 0.4  | 2.4    | 5.4    | 6.0    | 8.7             | 10.4  |
| Cash NRIs                                | -1.8 | 0.0    | 0.0  | 0.0    | 0.0    | 0.0    | 0.0             | 0.0   |
| Non-cash NRIs                            | 0.0  | 0.0    | 0.0  | 0.0    | 0.0    | 0.0    | 0.0             | 0.0   |
| BALANCE SHEET, EURm                      |      |        |      |        |        |        |                 |       |
| Assets                                   |      |        |      |        |        |        |                 |       |
| Fixed assets                             | 17   | 16     | 21   | 23     | 30     | 30     | 30              | 31    |
| Goodwill                                 | 10   | 13     | 13   | 13     | 13     | 13     | 13              | 13    |
| Right of use assets                      | 0    | 0      | 5    | 5      | 3      | 4      | 4               | 4     |
| Inventory                                | 9    | 12     | 15   | 17     | 16     | 19     | 21              | 22    |
| Receivables                              | 10   | 15     | 20   | 20     | 21     | 24     | 27              | 29    |
| Liquid funds                             | 7    | 8      | 5    | 7      | 12     | 14     | 15              | 16    |
| Total assets                             | 54   | 64     | 79   | 85     | 97     | 105    | 112             | 117   |
| Liabilities                              |      |        |      |        |        |        |                 |       |
| Shareholder's equity                     | 27   | 29     | 26   | 26     | 29     | 32     | 38              | 45    |
| Minority interest                        | 0    | 0      | 0    | 0      | 0      | 0      | 0               | 0     |
| Convertibles                             | 0    | 0      | 0    | 0      | 0      | 0      | 0               | 0     |
| Lease liabilities                        | 0    | 0      | 3    | 4      | 2      | 4      | 4               | 4     |
| Deferred taxes                           | 1    | 0      | 0    | 0      | 0      | 0      | 0               | 0     |
| Interest bearing debt                    | 14   | 16     | 30   | 32     | 40     | 39     | 37              | 33    |
| Non-interest bearing current liabilities | 12   | 18     | 18   | 21     | 24     | 28     | 31              | 33    |
| Other interest-free debt                 | 1    | 0      | 2    | 2      | 2      | 2      | 2               | 2     |
| Total liabilities                        | 54   | 64     | 79   | 85     | 97     | 105    | 112             | 117   |
| CASH FLOW, EURm                          |      |        |      |        |        |        |                 |       |
| + EBITDA                                 | 4    | 9      | 8    | 11     | 15     | 15     | 18              | 21    |
| - Net financial items                    | 0    | -1     | 0    | -1     | -2     | -1     | -1              | -1    |
| - Taxes                                  | 0    | -1     | -2   | -2     | -2     | -2     | -3              | -4    |
| - Increase in Net Working Capital        | 1    | -3     | -4   | 1      | 3      | -2     | -2              | -1    |
| +/- Other                                | -1   | 1      | 0    | 0      | 0      | 0      | 0               | 0     |
| = Cash flow from operations              | 3    | 5      | 1    | 8      | 13     | 10     | 13              | 15    |
| - Capex                                  | -3   | -3     | -10  | -8     | -13    | -7     | -6              | -6    |
| - Acquisitions                           | 0    | 0      | 0    | 0      | 0      | 0      | 0               | 0     |
| + Divestments                            | 0    | 0      | 0    | 0      | 0      | 0      | 0               | 0     |
| = Free cash flow                         | 0    | 1      | -9   | 1      | 0      | 3      | 6               | 9     |
| +/- New issues/buybacks                  | 0    | -1     | 0    | 0      | -1     | 0      | 0               | 0     |
| - Paid dividend                          | -3   | -1     | -4   | -2     | -2     | -2     | -3              | -4    |
| +/- Other                                |      | _      | _    |        | _      |        | 0               | 4     |
| +/- Other                                | 2    | 1<br>0 | 9    | 3<br>2 | 7<br>5 | 1<br>2 | - <u>2</u><br>1 | -4    |

Chemicals/Finland, September 17, 2021 Company update

| KEY FIGURES  | 2017                             | 2018                              | 2019                     | 2020                       | 2021E                    | 2022E                    | 2023E                    |
|--|----------------------------------|-----------------------------------|--------------------------|----------------------------|--------------------------|--------------------------|--------------------------|
| M-cap  | 78                               | 48                                | 78                       | 88                         | 102                      | 102                      | 102                      |
| Net debt (excl. convertibles)  | 9                                | 28                                | 29                       | 30                         | 29                       | 26                       | 21                       |
| Enterprise value   | 87                               | 76                                | 107                      | 118                        | 131                      | 128                      | 123                      |
| Sales  | 86                               | 97                                | 104                      | 109                        | 126                      | 139                      | 149                      |
| EBITDA   | 9                                | 8                                 | 11                       | 15                         | 15                       | 18                       | 21                       |
| EBIT   | 6                                | 2                                 | 5                        | 9                          | 9                        | 12                       | 15                       |
| Pre-tax  | 5                                | 2                                 | 4                        | 7                          | 8                        | 12                       | 14                       |
| Earnings   | 4                                | 0                                 | 2                        | 5                          | 6                        | 9                        | 10                       |
| Equity book value (excl. minorities)   | 29                               | 26                                | 26                       | 29                         | 32                       | 38                       | 45                       |
| Valuation multiples  |                                  |                                   |                          |                            |                          |                          |                          |
| EV/sales   | 1.0                              | 0.8                               | 1.0                      | 1.1                        | 1.0                      | 0.9                      | 0.8                      |
| EV/EBITDA  | 9.3                              | 9.9                               | 10.0                     | 7.7                        | 8.8                      | 7.0                      | 6.0                      |
| EV/EBITA   | 14.2                             | 34.5                              | 21.0                     | 12.5                       | 15.0                     | 10.3                     | 8.4                      |
| EV/EBIT  | 14.2                             | 34.5                              | 21.0                     | 12.5                       | 15.0                     | 10.3                     | 8.4                      |
| EV/OCF   | 17.7                             | 84.3                              | 12.9                     | 8.8                        | 13.1                     | 9.9                      | 8.2                      |
| EV/FCFF  | -28.4                            | -6.6                              | 32.5                     | 52.9                       | 24.0                     | 15.3                     | 11.8                     |
| P/FCFE   | 55.8                             | -5.5                              | 110.9                    | 179.1                      | 31.6                     | 15.7                     | 11.9                     |
| P/E  | 18.6                             | 119.0                             | 32.5                     | 16.4                       | 17.1                     | 11.8                     | 9.8                      |
| P/B  | 2.7                              | 1.8                               | 3.0                      | 3.1                        | 3.2                      | 2.7                      | 2.3                      |
| Target EV/EBITDA   | 0.0                              | 0.0                               | 0.0                      | 0.0                        | 9.9                      | 7.9                      | 6.8                      |
| Target EV/EBIT   | 0.0                              | 0.0                               | 0.0                      | 0.0                        | 16.9                     | 11.7                     | 9.5                      |
| Target EV/FCF  | 0.0                              | 0.0                               | 0.0                      | 0.0                        | 45.9                     | 22.3                     | 16.2                     |
| Target P/B   | 0.0                              | 0.0                               | 0.0                      | 0.0                        | 3.7                      | 3.1                      | 2.7                      |
| Target P/E   | 0.0                              | 0.0                               | 0.0                      | 0.0                        | 19.9                     | 13.7                     | 11.4                     |
| Per share measures   | 0.0                              | 0.0                               | 0.0                      | 0.0                        | 70.0                     | 70.7                     | ,,,,                     |
| Number of shares   | 11,897                           | 11,897                            | 11,897                   | 11,897                     | 11,897                   | 11,897                   | 11,897                   |
| Number of shares (diluted)   | 11,897                           | 11,897                            | 11,897                   | 11,897                     | 11,897                   | 11,897                   | 11,897                   |
| EPS (unated)   | 0.35                             | 0.03                              | 0.20                     | 0.45                       | 0.50                     | 0.73                     | 0.88                     |
| Operating cash flow per share  | 0.41                             | 0.08                              | 0.70                     | 1.12                       | 0.84                     | 1.08                     | 1.26                     |
| Free cash flow per share   | 0.12                             | -0.73                             | 0.06                     | 0.04                       | 0.27                     | 0.55                     | 0.72                     |
| Book value per share   | 2.42                             | 2.16                              | 2.21                     | 2.41                       | 2.72                     | 3.19                     | 3.77                     |
| Dividend per share   | 0.30                             | 0.18                              | 0.18                     | 0.20                       | 0.25                     | 0.30                     | 0.32                     |
| Dividend payout ratio, %   | 85.0                             | 535.4                             | 89.2                     | 44.3                       | 49.8                     | 41.2                     | 36.5                     |
| Dividend yield, %  | 4.6                              | 4.5                               | 2.7                      | 2.7                        | 2.9                      | 3.5                      | 3.7                      |
| FCF yield, %   | 1.8                              | -18.3                             | 0.9                      | 0.6                        | 3.2                      | 6.4                      | 8.4                      |
| Efficiency measures  | 1.0                              | 10.0                              | 0.0                      | 0.0                        | 5.2                      | 0.1                      | 0.1                      |
| ROE  | 15.2                             | 1.5                               | 9.2                      | 19.5                       | 19.6                     | 24.6                     | 25.1                     |
| ROCE   | 14.6                             | 4.5                               | 8.6                      | 14.4                       | 12.3                     | 16.3                     | 18.5                     |
| Financial ratios   | 11.0                             | 1.0                               | 0.0                      |                            | 12.0                     | 10.0                     | 10.0                     |
| Inventories as % of sales  | 13.5                             | 15.7                              | 16.3                     | 14.9                       | 14.9                     | 14.9                     | 14.9                     |
| Receivables as % of sales  | 17.1                             | 20.8                              | 19.2                     | 19.2                       | 19.2                     | 19.2                     | 19.2                     |
| Trecerrations as to or saires  |                                  | 19.2                              | 20.2                     | 22.0                       | 22.0                     | 22.0                     | 22.0                     |
| Non-interest bearing liabilities as % of sales   | 21.4                             |                                   |                          |                            |                          |                          |                          |
| Non-interest bearing liabilities as % of sales<br>NWC/sales. %   | 21.4<br>9.3                      |                                   | 14 1                     | 11 2                       | 11.3                     | 114                      | 114                      |
| NWC/sales, %   | 9.3                              | 16.1                              | 14.1<br>7.3              | 11.2<br>11.9               | 11.3<br>5.4              | 11.4<br>4.6              | 11.4                     |
| NWC/sales, %<br>Operative CAPEX/sales, %   | 9.3<br>4.1                       | 16.1<br>9.9                       | 7.3                      | 11.9                       | 5.4                      | 4.6                      | 4.3                      |
| NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %  | 9.3<br>4.1<br>4.1                | 16.1<br>9.9<br>9.9                | 7.3<br>7.3               | 11.9<br>11.9               | 5.4<br>5.4               | 4.6<br>4.6               | 4.3<br>4.3               |
| NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA                                | 9.3<br>4.1<br>4.1<br>-0.3        | 16.1<br>9.9<br>9.9<br>-1.5        | 7.3<br>7.3<br>0.3        | 11.9<br>11.9<br>0.1        | 5.4<br>5.4<br>0.4        | 4.6<br>4.6<br>0.5        | 4.3<br>4.3<br>0.5        |
| NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted | 9.3<br>4.1<br>4.1<br>-0.3<br>0.9 | 16.1<br>9.9<br>9.9<br>-1.5<br>3.7 | 7.3<br>7.3<br>0.3<br>2.7 | 11.9<br>11.9<br>0.1<br>2.0 | 5.4<br>5.4<br>0.4<br>2.0 | 4.6<br>4.6<br>0.5<br>1.4 | 4.3<br>4.3<br>0.5<br>1.0 |
| NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA                                | 9.3<br>4.1<br>4.1<br>-0.3        | 16.1<br>9.9<br>9.9<br>-1.5        | 7.3<br>7.3<br>0.3        | 11.9<br>11.9<br>0.1        | 5.4<br>5.4<br>0.4        | 4.6<br>4.6<br>0.5        | 4.3<br>4.3<br>0.5        |

#### **EVLI EQUITY RESEARCH**

## **EXEL COMPOSITES**

Chemicals/Finland, September 17, 2021 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

| OWNERSHIP STRUCTURE                          | SHARES     | EURm    | 0/0   |
|--|------------|---------|-------|
| Skandinaviska Enskilda Banken AB             | 1,464,492  | 12.580  | 12.3% |
| Nordea Bank ABP                              | 1,018,305  | 8.747   | 8.6%  |
| Sijoitusrahasto Taaleritehdas Mikro Markka   | 800,000    | 6.872   | 6.7%  |
| OP-Finland Small Firms Fund                  | 598,259    | 5.139   | 5.0%  |
| Danske Invest Finnish Equity Fund            | 520,000    | 4.467   | 4.4%  |
| Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto | 450,000    | 3.866   | 3.8%  |
| Phoebus Fund                                 | 311,348    | 2.674   | 2.6%  |
| Säästöpankki Pienyhtiöt                      | 288,710    | 2.480   | 2.4%  |
| Ilmarinen Mutual Pension Insurance           | 242,733    | 2.085   | 2.0%  |
| Veritas Pension Insurance Company Ltd.       | 226,163    | 1.943   | 1.9%  |
| Ten largest                                  | 5,920,010  | 50.853  | 50%   |
| Residual                                     | 5,976,833  | 51.341  | 50%   |
| Total  | 11,896,843 | 102.194 | 100%  |

| EARNINGS CALENDAR |           |
|-------------------|-----------|
| November 04, 2021 | Q3 report |
|                   |           |
|                   |           |
|                   |           |
| OTHER EVENTS      |           |

COMPANY MISCELLANEOUS
CEO: Riku Kytömäki Mäkituvantie 5 01510 Vantaa
CFO: Mikko Kettunen Tel: +358 20 7541 200
IR: Noora Koikkalainen

Chemicals/Finland, September 17, 2021 Company update

#### **DEFINITIONS**

| re extraord. items and taxes- income taxes + minority interest  Number of shares          |
|---|
|   |
| Dividend for the financial period per share   |
| cash flow)  |
| Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments |
| flow)   |
| sh flow – operative CAPEX – acquisitions + divestments                                    |
|   |
| Free cash flow Market cap   |
| EX/sales  |
| tal expenditure – divestments – acquisitions<br>Sales                                     |
| pital   |
| Current assets – current liabilities  |
| ed/Share  |
| otal assets – non-interest bearing debt<br>Number of shares                               |
|   |
| Net debt<br>Equity  |
|   |
| Interest bearing debt<br>ders' equity + minority interest + taxed provisions              |
|   |
| lers' equity + minority interest + taxed provisions  Total assets – interest-free loans   |
|   |
| ve annual growth rate = Average growth per year   |
|   |
|   |
|   |

Chemicals/Finland, September 17, 2021 Company update

#### Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

#### Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Bank Plc. Production of the investment recommendation has been concluded on [17.9.2021, 9:30]. This report has been published on [17.9.2021, 9:45].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or Evli. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

#### **EVLI EQUITY RESEARCH**

## **EXEL COMPOSITES**

Chemicals/Finland, September 17, 2021 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Bank Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Bank Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli Bank is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Bank Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, September 17, 2021 Company update

# Contact information SALES, TRADING AND RESEARCH

| Equity, ETF and Derivatives Sales                            |  | Trading  |  |
|--|--|--|--|
| Joachim Dannberg<br>Ari Laine<br>Kimmo Lilja                 | +358 9 4766 9123<br>+358 9 4766 9115<br>+358 9 4766 9130 | Lauri Vehkaluoto (Head)<br>Pasi Väisänen<br>Antti Kässi<br>Miika Ronkanen                  | +358 9 4766 9120<br>+358 9 4766 9120<br>+358 9 4766 9120<br>+358 9 4766 9120                     |
| Structured Investments                                       |  | Equity Research  |  |
| Heikki Savijoki<br>Aki Lakkisto<br>Evli Investment Solutions | +358 9 4766 9726<br>+358 9 4766 9123                     | Jonas Forslund<br>Joonas Ilvonen<br>Jerker Salokivi<br>Anna-Liisa Rissanen<br>Teemu Reiman | +358 9 4766 9314<br>+358 44 430 9071<br>+358 9 4766 9149<br>+358 40 157 9919<br>+358 40 352 6175 |
| Johannes Asuja<br>Markku Reinikainen                         | +358 9 4766 9205<br>+358 9 4766 9669                     |  |  |



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001